** Drug developer Keros Therapeutics' KROS.O shares rise 3.6% to $58.78
** KROS says it entered into a global license agreement with Takeda 4502.T for experimental drug elritercept
** Elritercept is being developed to treat low blood cell counts in patients with myelodysplastic syndrome and myelofibrosis, which are blood cancers
** KROS to receive $200 mln upfront and potentially over $1.1 bln in milestone payments from Takeda
** Upfront payment will extend KROS' operational runway into Q4 2028, co says
** Brokerage Truist Securities believes the partnership eases concerns about KROS’s ability to commercialize in different areas
** Brokerage Guggenheim Securities says the partnership allows Keros to focus on the development of cibotercept for the treatment of pulmonary arterial hypertension
** The agreement excludes commercialization in mainland China, Hong Kong, and Macau
** All 15 brokerages rate the stock "buy" or higher; their median PT is $92 - LSEG
** Including session's gains, stock has risen 43.4% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.